Navigation Links
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD

Non-stimulant drug addresses wide range of symptoms of ADHD

DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.

The study showed that the new drug, Clonicel, achieved statistically significant improvement over placebo in reducing an aggregate of 18 ADHD symptoms listed by the American Psychiatric Association and used by physicians to diagnose and classify the condition.

"This is the first study to validate the potential for a long-acting version of clonidine -- a widely used hypertension drug -- as a safe and effective treatment for ADHD," said Moise Khayrallah, Ph.D., CEO of Addrenex Pharmaceuticals, a small Durham start-up that initiated and coordinated the multicenter trial.

Previous studies of clonidine have indicated that the drug diminishes select symptoms of ADHD, but these studies have been small and inconclusive, Khayrallah said. Moreover, clonidine carries bothersome side effects that have limited its use, including a peak of drowsiness when the drug is absorbed and a subsequent rebound of symptoms when drug levels subside.

Addrenex scientists developed Clonicel to reduce these side effects and treat specific ADHD symptoms that may occur when the body's adrenergic system is in overdrive, producing excessive levels of the stress hormone adrenaline. Such symptoms include emotional outbursts, mood swings, insomnia and hyperreactivity to stress.

"We conducted a well-powered, randomized clinical trial to demonstrate that Clonicel may be effective on its own in treating a multitude of ADHD symptoms, with a favorable side effect profile," said Khayrallah. "We're very excited with the positive data we obtained, and we intend for this study to serve as part of the basis for review and approval by the FDA, hopefully by next year."

The study showed that Clonicel was statistically superior to placebo on the primary endpoint, the ADHD Rating Scale of 18 symptoms. Clonicel was also statistically superior to placebo on several secondary scales completed by clinicians and parents, including a scale that assesses adrenergic dysregulation. The scale was designed by Joseph Horacek, M.D., a Charlotte neuropsychiatrist and cofounder of Addrenex. Side effects were generally mild to moderate in severity, and no serious adverse events were reported in the study.

A total of 228 children between the ages of 6 and 17 with a diagnosis of ADHD participated in the randomized, double-blind, placebo-controlled trial that compared two doses of Clonicel, 0.2 mg per day and 0.4 mg per day, with placebo. Children received either study medication or placebo for eight weeks at one of 13 study centers nationwide.

If Clonicel is approved by the Food and Drug Administration, the new drug will be marketed by Sciele Pharma under an agreement signed with Addrenex in July 2007.

The introduction of Clonicel into the ADHD market would fill a void that currently exists in the treatment of ADHD, Khayrallah said. While stimulants play an important role in treating ADHD, they do not address all of the symptoms associated with the disorder and may result in unacceptable side effects in some patients.

Because Clonicel targets receptors within the body's stress response center -- the adrenergic system -- it may be more effective in alleviating lesser-known symptoms that accompany ADHD, such as emotional outbursts, mood swings, irritability and hyperreactivity to stress, Horacek said.

"We believe that Clonicel is normalizing the excess of the adrenergic hormones that contribute to many of the symptoms of ADHD," said Horacek.

Stress hormones produce a rapid heart rate, elevated blood pressure, sweating, temperature increases, heightened anxiety, stress and fear, he said. Scientists have implicated an excessive stress response to a wide array of disorders, from ADHD and Tourette's syndrome to post-traumatic stress disorder and migraines.

Addrenex is currently developing a cadre of drugs focused on treating these and other conditions arising from adrenergic excess, including hypertension, menopausal flushing, pain and sleep disturbance. By mining a library of 400 adrenergic compounds at the University of Nebraska Medical Center, Addrenex scientists have already identified one new drug candidate, a compound code named ADX415, to treat hypertension and other conditions.

"With the extremely positive data from our first study, we are well under way toward our goal of regulating adrenergic excess and helping to ameliorate medical conditions that arise from this physiologic imbalance," said Khayrallah.

The company is also midway through a second ADHD clinical trial testing the effects of Clonicel together with stimulants. The goal is to determine if the two treatments together alleviate a broader range of symptoms than either drug alone.

SOURCE Addrenex
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
9. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  PTS Diagnostics, the U.S.-based manufacturer ... analyzers, A1CNow ® systems, and PTS Detect™ ... of patents that will propel the company into the ... Europe . The technology is a ... those on smartphones and tablets, and uses test strip ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), ... present live at on December 3, 2015. ... TIME: 3:15p.m. ET LINK: ... LINK: --> ... event where investors are invited to ask the company questions ...
(Date:11/30/2015)... LAKE CITY , Nov. 30, 2015 Booth ... (NYSE: VAR ) will exhibit a broader array of ... of the Radiological Society of North America ... Varian exhibit at the meeting will feature X-ray components "At ... CT tube, a line of products from Varian,s Claymount brand, ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... During ... information for caregivers and held two webinars on topics of ‘Medical and Palliative ... of charge at . , With a loved one's diagnosis of ...
(Date:11/30/2015)... TX (PRWEB) , ... November 30, 2015 , ... ... plastic surgery and dermatology, is proud to announce that its ThermiRFR temperature controlled ... , ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as a ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... vehicle experience this summer, ushering in a new era of publicly accessible automated ... electric shuttle, will continue to offer guests an up-close look at the shuttle ...
(Date:11/30/2015)... ... ... On Saturday, October 24th, 2015, at the Mill Race Park in Downtown ... walk known as “Making Strides Against Breast Cancer”. Patients and staff members from A ... Battle Creek, joined in for this campaign that sought to raise donations that will ...
(Date:11/30/2015)... Alexandria, VA (PRWEB) , ... November 30, 2015 ... ... Research Foundation kicked off its annual fundraising campaign to raise funds for its ... usually raises approximately 10% of the organization’s annual funding. , The Mesothelioma Applied ...
Breaking Medicine News(10 mins):